Dr. Demetri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Dana-Farber Cancer Institute
Boston, MA 02215Phone+1 617-632-5204Fax+1 617-632-3408
Summary
- Dr. George Demetri is an oncologist in Boston, MA and is affiliated with multiple hospitals affiliated with Harvard Medical School in the area, primarily the Dana-Farber Cancer Institute. He received his medical degree from Stanford University School of Medicine and has been in practice 34 years. He specializes in Sarcomas and Developmental Therapeutics
.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1985 - 1989
- University of WashingtonResidency, Internal Medicine, 1983 - 1985
- Stanford University School of MedicineClass of 1983
Certifications & Licensure
- FL State Medical License 2022 - Present
- MA State Medical License 1986 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow (FASCO) American Society of Clinical Oncologists, 2008
- Super Doctor SuperDoctors.com
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Troglitazone in Treating Patients With Liposarcoma Start of enrollment: 1997 Jun 01
- Bexarotene in Treating Patients With Metastatic Breast Cancer Start of enrollment: 1998 Oct 01
- Rosiglitazone in Treating Patients With Liposarcoma Start of enrollment: 1999 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 1759 citationsPDGFRA Activating Mutations in Gastrointestinal Stromal TumorsMichael Heinrich, Christopher L. Corless, Anette Duensing, Laura McGreevey, Chang Jie Chen
Science. 2003-01-31 - 419 citationsNCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.George D. Demetri, Robert S. Benjamin, Charles D. Blanke, Jean-Yves Blay, Paolo G. Casali
Journal of the National Comprehensive Cancer Network. 2007-07-01 - 793 citationsNCCN Task Force report: update on the management of patients with gastrointestinal stromal tumorsGeorge D. Demetri, Margaret von Mehren, Cristina R. Antonescu, Ronald P. DeMatteo, Kristen N. Ganjoo
Journal of the National Comprehensive Cancer Network. 2010-04-01
Lectures
- First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.2019 ASCO Annual Meeting - 6/1/2019
Other
- Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumorsDemetri GD, Raut CP, Morgan J
http://www.uptodate.com/contents/adjuvant-and-neoadjuvant-imatinib-for-gastrointestinal-stromal-tumo
UpToDate, Wolters Kluwer Health - 2013-01-15 - Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GISTDemetri GD, Raut CP, Morgan J
http://www.uptodate.com/contents/epidemiology-classification-clinical-presentation-prognostic-featur
UpToDate, Wolters Kluwer Health - 2013-02-04 - Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tractDemetri GD, Raut CP, Morgan J
http://www.uptodate.com/contents/local-treatment-for-gastrointestinal-stromal-tumors-leiomyomas-and-
UpToDate, Wolters Kluwer Health - 2013-01-16 - Join now to see all
Press Mentions
- For New NCI Director, Work Turns Personal: She Is Diagnosed with CancerDecember 14th, 2022
- Cancer Combination Therapy Company IDRx Launches with $122M Series a FundingAugust 2nd, 2022
- Sylvester’s Outstanding Faculty for 2022: In Their Own WordsJuly 15th, 2022
- Join now to see all
Grant Support
- Targeted Therapy Resistance Mechanisms In Gastrointestinal Stromal Tumor(Gist)National Cancer Institute2007–2011
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: